Recent progress in allogeneic stem cell transplantation

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 4, 2008, Pages 343-349

  Mattsson, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Allogeneic stem cell transplantation; Graft versus host disease; Graft versus tumor effect; Leukemia; Solid tumor

Indexed keywords

AZATHIOPRINE; BORTEZOMIB; BUSULFAN; CASPASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; HISTOCOMPATIBILITY ANTIGEN; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROBIOTIC AGENT; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DRUG SUBSTITUTION; ENZYME POLYMORPHISM; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MALIGNANT NEOPLASTIC DISEASE; MESENCHYMAL STEM CELL; MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; PATHOPHYSIOLOGY; PERIPHERAL CIRCULATION; REDUCED INTENSITY CONDITIONING; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR; UMBILICAL CORD BLOOD; WHOLE BODY RADIATION;

ANIMALS; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; STEM CELL TRANSPLANTATION; STEM CELLS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 49249102171     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Thomas ED, Lochte HLJ, Lu WC, Ferrebee JW: Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med (1957) 257(11):491-496.
2. Hinterberger W, Hinterberger-Fischer M, Marmont A: Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases. Bone Marrow Transplant (2002) 30(11):753-759. •• This trial demonstrated that ASCT may be a treatment option for patients with autoimmune disorders.
3. Hurley CK, Raffoux C: World Marrow Donor Association: International standards for unrelated hematopoietic stem cell donor registries. Bone Marrow Transplant (2004) 34(2):103-110.
4. Petersdorf EW, Malkki M: Human leukocyte antigen matching in unrelated donor hematopoietic cell transplantation. Semin Hematol (2005) 42(2):76-84.
5. Ringden O, Schaffer M, Le Blanc K, Persson U, Hauzenberger D, Abedi MR, Olerup O, Ljungman P, Remberger M: Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers? Biol Blood Marrow Transplant (2004) 10(2):128-134.
6. Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N, Chehata S, Esperou H, Vernant JP, Michallet M, Buzyn A et al: Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: A prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol (2006) 24(36):5695-5702. •• This trial showed that the same data were obtained when unrelated donors are used for ASCT compared with sibling donors.
7. Remberger M, Mattsson J, Hausenberger D, Schaffer M, Svahn BM, Ringden O: Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia. Eur J Haematol (2008) 80(5):419-428.
8. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M et al: Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood (2003) 101(4):1620-1629.
9. Uzunel M, Remberger M, Sairafi D, Hassan Z, Mattsson J, Omazic B, Barkholt L, Ringden O: Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. Transplantation (2006) 82(7):913-919.
10. Ringden O, Labopin M, Bacigalupo A, Arcese W, Schaefer UW, Willemze R, Koc H, Bunjes D, Gluckman E, Rocha V, Schattenberg A, Frassoni F: Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol (2002) 20(24):4655-4664.
11. Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringden O: Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood (2005) 105(2):548-551.
12. Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR Jr, Ringden O, Wagner JE: Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol (2004) 22(24):4872- 4880. •• An important trial that suggested bone marrow should be utilized as a stem cell source in children.
13. Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD, Loberiza FR, Gratwohl A, Champlin RE: Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood (2006) 108(13):4288-4290.
14. Rocha V, Gluckman E: Clinical use of umbilical cord blood hematopoietic stem cells. Biol Blood Marrow Transplant (2006) 12(1 Suppl 1):34-41. •• An informative overview of the use of cord blood in ASCT.
15. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE: Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood (2003) 102(5):1915-1919. •• The first trial suggesting that infusion of two units of cord blood in adults provides sufficient numbers of stem cells.
16. Ballen KK: New trends in umbilical cord blood transplantation. Blood (2005) 105(10):3786-3792.
17. Tomizawa D, Aoki Y, Nagasawa M, Morio T, Kajiwara M, Sekine T, Shimizu N, Kato M, Yachie A, Mizutani S: Novel adopted immunotherapy for mixed chimerism after unrelated cord blood transplantation in Omenn syndrome. Eur J Haematol (2005) 75(5):441-444.
18. Storb R, Thomas ED: Allogeneic bone-marrow transplantation. Immunol Rev (1983) 71:77-102.
19. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, Braine HG, Burns WH, Elfenbein GJ, Kaizer H: Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med (1983) 309(22):1347-1353.
20. Tutschka PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood (1987) 70(5):1382-1388.
21. Sweetenham JW: Diffuse large B-cell lymphoma: Risk stratification and management of relapsed disease. Hematology Am Soc Hematol Educ Program (2005):252-259.
22. Appelbaum FR: Dose intensity and the toxicity and efficacy of allogeneic hematopoietic cell transplantation. Leukemia (2005) 19(2):171-175.
23. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood (1998) 91(3):756-763.
24. Barrett AJ, Savani BN: Stem cell transplantation with reduced-intensity conditioning regimens: A review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia (2006) 20(10):1661-1672. • A comprehensive overview of the use of RIC ASCT over the last 10 years.
25. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG, Sandmaier BM, Storb R: Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood (2004) 104(5):1550-1558.
26. Le Blanc K, Remberger M, Uzunel M, Mattsson J, Barkholt L, Ringden O: A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. Transplantation (2004) 78(7):1014-1020.
27. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, Juliusson G, Nagler A, Gratwohl A, Passweg J, Komarnicki M et al: Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: An analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood (2005) 106(9):2969-2976.
28. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J et al: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med (1986) 314(12):729-735.
29. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D et al: Phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood (2000) 96(6):2062-2068.
30. Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, Antin JH: Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood (2006) 109(7):3108-3114. •• An interesting trial that suggested sirolimus may be an option for GVHD prophylaxis after ASCT.
31. Bacigalupo A: Antithymocyte globulin for prevention of graft-versus-host disease. Curr Opin Hematol (2005) 12(6):457-462.
32. Remberger M, Storer B, Ringden O, Anasetti C: Association between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant (2002) 29(5):391-397.
33. Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, Oneto R, Bruno B, Sacchi N, van Lint MT, Bosi A: Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant (2006) 12(5):560-565.
34. Remberger M, Svahn BM, Mattsson J, Ringden O: Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation (2004) 78(1):122-127.
35. Remberger M, Sundberg B: Rabbit-immunoglobulin G levels in patients receiving thymoglobulin as part of conditioning before unrelated donor stem cell transplantation. Hematologica (2005) 90(7):931-938.
36. Svahn BM, Remberger M, Myrback KE, Holmberg K, Eriksson B, Hentschke P, Aschan J, Barkholt L, Ringden O: Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood (2002) 100(13):4317-4324.
37. Svahn BM, Ringden O, Remberger M: Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant (2005) 36(6):511-516. •• An important trial that demonstrated patients can be treated safely at home after ASCT.
38. Mattsson J, Westin S, Edlund S, Remberger M: Poor oral nutrition after allogeneic stem cell transplantation correlates significantly with severe graft-versus-host disease. Bone Marrow Transplant (2006) 38(9):629-633.
39. Gerbitz A, Schultz M, Wilke A, Linde HJ, Scholmerich J, Andreesen R, Holler E: Probiotic effects on experimental graft-versus-host disease: Let them eat yogurt. Blood (2004) 103(11):4365-4367.
40. Ringden O: Introduction to graft-versus-host disease. Biol Blood Marrow Transplant (2005) 11(2 Suppl 2):17-20.
41. Ferrara JL, Reddy P: Pathophysiology of graft-versus-host disease. Semin Hematol (2006) 43(1):3-10. •• An elegant review of the mechanisms of GVHD action.
42. Stern M, Passweg JR, Locasciulli A, Socie G, Schrezenmeier H, Bekassy AN, Fuehrer M, Hows J, Korthof ET, McCann S, Tichelli A et al: Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia. Transplantation (2006) 82(2):218-226.
43. Jaksch M, Remberger M, Mattsson J: Increased immune transcript levels are correlated with acute graft-versus-host disease and cytomegalovirus response after allogeneic stem cell transplantation. Transplantation (2004) 77(2):195-200.
44. Jaksch M, Remberger M, Mattsson J: Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2005) 11(4):280-287.
45. Srinivasan R, Daniels J, Fusaro V, Lundqvist A, Killian JK, Geho D, Quezado M, Kleiner D, Rucker S, Espina V, Whiteley G et al: Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol (2006) 34(6):796-801. • A study that suggests proteomics may be a useful tool in diagnosing GVHD.
46. Holler E, Rogler G, Herfarth H, Brenmoehl J, Wild PJ, Hahn J, Eissner G, Scholmerich J, Andreesen R: Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GVHD following allogeneic stem cell transplantation. Blood (2004) 104(3):889-894.
47. Sairafi D, Uzunel M, Remberger M, Ringden O, Mattsson J: No impact of NOD2/CARD15 on outcome after SCT. Bone Marrow Transplant (2008) 41(11):961-964.
48. Mayor NP, Shaw BE, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S, Marsh SG: Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. J Clin Oncol (2007) 25(27):4262-4269.
49. Wood KJ, Sakaguchi S: Regulatory T cells in transplantation tolerance. Nat Rev Immunol (2003) 3(3):199-210.
50. Stanzani M, Martins SL, Saliba RM, St John LS, Bryan S, Couriel D, McMannis J, Champlin RE, Molldrem JJ, Komanduri KV: CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood (2004) 103(3):1140-1146.
51. Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J, Keyvanfar K, Montero A, Hensel N, Kurlander R, Barrett AJ: High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood (2006) 108(4):1291-1297.
52. Janson PC, Winerdal ME, Marits P, Thorn M, Ohlsson R, Winqvist O: FOXP3 promoter demethylation reveals the committed Treg population in humans. PLoS ONE (2008) 3(2):e1612.
53. Le Blanc K, Ringden O: Mesenchymal stem cells: Properties and role in clinical bone marrow transplantation. Curr Opin Immunol (2006) 18(5):586-591.
54. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lonnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z, Omazic B et al: Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation (2006) 81(10):1390-1397.
55. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G et al: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet (2008) 371(9624):1579-1586. •• An important trial which suggested that MSCs may provide a treatment option for patients with severe steroid-resistant GVHD.
56. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R et al: Rituximab for steroid-refractory chronic graft-versus-host disease. Blood (2006) 108(2):756-762.
57. Hogan WJ, Deeg HJ: Stem cell transplantation: Graft-mediated antileukemia effects. Methods Mol Med (2005) 109:421-444.
58. Goulmy E: Minor histocompatibility antigens: From transplantation problems to therapy of cancer. Hum Immunol (2006) 67(6):433-438.
59. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL: A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med (2005) 11(11):1244- 1249.
60. Saito TI, Rubio MT, Sykes M: Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation. Exp Hematol (2006) 34(9):1271-1277.
61. Dey BR, McAfee S, Colby C, Cieply K, Caron M, Saidman S, Preffer F, Shaffer J, Tarbell N, Sackstein R, Sachs D et al: Antitumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol (2005) 128(3):351-359.
62. Kroger N, Zabelina T, Ayuk F, Atanackovic D, Schieder H, Renges H, Zander A: Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol (2006) 34(6):770-775.
63. Dey BR, Spitzer TR: Current status of haploidentical stem cell transplantation. Br J Haematol (2006) 135(4):423-437.
64. Ruggeri L, Aversa F, Martelli MF, Velardi A: Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev (2006) 214(1):202-218.
65. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 295(5562):2097-2100.
66. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, Velardi A, Blazar BR: Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood (2002) 100(10):3825-3827.
67. Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, Maccario R, Bonetti F, Wojnar J, Martinetti M, Frassoni F et al: Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 102(3):814-819.
68. Schaffer M, Malmberg KJ, Ringdén O, Ljunggren HG, Remberger M: Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation (2004) 78(7):1081-1085.
69. Childs RW, Srinivasan R: Allogeneic hematopoietic cell transplantation for solid tumors. In: Thomas' Hematopoietic Cell Transplantation. Blume KG, Forman SJ, Appelbaum FR (Eds), Blackwell Publishing Ltd, Malden, MA, USA (2004):1177-1187.
70. Barkholt L, Bregni M, Remberger M, Blaise D, Peccatori J, Massenkeil G, Pedrazzoli P, Zambelli A, Bay JO, Francois S, Martino R et al: Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. Ann Oncol (2006) 17(7):1134-1140.
71. Takahashi Y, Harashima N, Kajigaya S, Yokoyama H, Cherkasova E, McCoy JP, Hanada K, Mena O, Kurlander R, Tawab A, Srinivasan R et al: Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest (2008) 118(3):1099-1109. •• An important trial that, for the first time, showed the presence of a solid tumor antigen in patients with RCC following ASCT. This observation may enable adoptive immunotherapy.